Allogeneic tumor cell vaccination

Patent metadata

Field	Value
Publication number	US-9301998-B2
Application number	US-201314081761-A
Country	US
Kind code	B2
Filing date	Nov 15, 2013
Priority date	May 17, 2011
Publication date	Apr 5, 2016
Grant date	Apr 5, 2016

Abstract

The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.

First claim

What is claimed is:

1. A tumor cell line selected from the group consisting of human cell lines designated SH-M-20, SH-M-20-A2, SH-M-21, SH-O-30 and SH-L-40 that are deposited in the European Collection of Cell Cultures (ECACC) Health Protection Agency under the accession numbers 11052602, 11052604, 11052601, 11052603 and 11052605, respectively.

2. A cell line obtained from a tumor cell line selected from the group consisting of SH-M-20, SH-M-20-A2, SH-M-21, SH-O-30 and SH-L-40 engineered to stably express an additional exogenous Human Leukocyte Antigen (HLA) and/or co-stimulatory molecule for T cells.

3. The cell line of claim 2 , stably expressing at least one of HLA-A2, 4-1BB ligand (4-1BBL) and HLA-B35.

4. A melanoma cell line according to claim 1 , said cell line designated SH-M-20 and deposited under the accession number 11052602.

5. The melanoma cell line of claim 1 , said cell line designated SH-M-20-A2 and deposited under the accession number 11052604.

6. An immunogenic composition comprising as an active ingredient at least one tumor cell line as defined in claim 1 .

7. A method of enhancing an immune response to a tumor in a subject in need thereof, said method comprising administering to the subject an immunogenic composition according to claim 6 , thereby enhancing the immune response in said subject.

8. A therapeutic composition for treating, ameliorating or reducing cancer in a mammalian subject, said therapeutic composition made by a method comprising the steps of selecting a subject, and providing a composition comprising one or more cell lines allogeneic to the subject, wherein at least one of said cell lines expresses at least one HLA allele identical to the HLA alleles of said subject, and wherein at least one of said cell lines endogenously or exogenously express the HLA-B35 and HLA-A2 alleles and 4-1BBL, said composition further comprising one or more pharmaceutically acceptable carrier, diluent, excipient, hapten, adjuvant or additive.

9. The composition of claim 8 comprising at least two cell lines allogeneic to said subject, or wherein said at least one of said cell lines expresses at least one HLA antigen and/or tumor associated antigens selected from the group consisting of A24, A33, B35, B49, CW04/12, A2/24, A03/25, B08/18, DRB1, A26, A28, B35, DRB01, DRB104, GD3, S-100, HMB45, Melan A/MART-I, HMW, MSCA, CD146, MAGE-A1, MAGE-A3, NY-ESO-1, CEA, PAN cytokeratin, Ca-125-sec, CEA-sec, CA15-3-sec and MUC-1.

10. The composition of claim 8 , wherein at least one of said cell lines is a tumor cell line as defined in claim 1 .

11. A therapeutic composition for treating, ameliorating, or reducing cancer in a mammalian subject, said therapeutic composition made by a method comprising the steps of selecting a subject and providing a composition comprising at least two cell lines allogeneic to the subject, wherein at least one of said cell lines expresses at least one HLA allele identical to the HLA alleles of said subject, and wherein at least one of said cell lines endogenously or exogenously express the HLA-B35 allele, said composition further comprising a pharmaceutically acceptable carrier, diluent, excipient, hapten, adjuvant or additive, wherein:
at least one of said cell lines expresses the HLA antigens A24, A33, B35, B49 and CW04/12, and the tumor associated antigens GD3, S-100, gp 100, Melan A/MART-I, HMW, MSCA, CD146, MAGE-A1 and MAGE-A3, or
at least one of said cell lines expresses the HLA antigens A2/24, and B35, and the tumor associated antigens S-100, GD3, MAGE-A1, MAGE-A3 and NY-ESO, or
at least one of said cell lines expresses the HLA antigens A26, A28, B14, B35, DRB01 and DRB104, and the tumor associated antigens, PAN cytokeratin, CEA, MAGE, and MUC-1, or
at least one of said cell lines expresses the HLA antigens A03/25, B08/18, and DRB1, and the tumor associated antigens CEA, Ca-125-sec and CEA-sec.

12. The therapeutic composition of claim 11 , wherein at least one of said cell lines expresses the HLA antigens A24, A33, B35, B49 and CW04/12, and the tumor associated antigens GD3, S-100, gp 100, Melan A/MART-I, HMW, MSCA, CD146, MAGE-A1 and MAGE-A3.

13. The therapeutic composition of claim 12 , wherein said cell line is a melanoma cell line designated SH-M-20 and deposited under the accession number 11052602.

14. The therapeutic composition of claim 12 , wherein said cell line is a melanoma cell line designated SH-M-20-A2 and deposited under the accession number 11052604.

15. The therapeutic composition of claim 11 , wherein at least one of said cell lines expresses the HLA antigens A2/24 and B35, and the tumor associated antigens S-100, GD3, MAGE-A1, MAGE-A3 and NY-ESO, or
wherein at least one of said cell lines expresses the HLA antigens A26, A28, B14, B35, DRB01 and DRB104 and the tumor associated antigens, PAN cytokeratin, CEA, MAGE, and MUC-1, or
wherein at least one of said cell lines expresses the HLA antigens A03/25, B08/18 and DRB1, and the tumor associated antigens CEA, Ca-125-sec and CEA-sec.

16. The therapeutic composition of claim 15 , wherein at least one of said cell lines is a melanoma cell line designated SH-M-21 and deposited under the accession number 11052601, a lung metastasis carcinoma cell line designated SH-L-40 and deposited under the accession number 11052605, or an ovary carcinoma cell line designated SH-O-30 and deposited under the accession number 11052603.

17. A method of treating cancer in a subject in need thereof, comprising:
identifying the subject that will respond therapeutically to the method of treating cancer by determining the expression of the B35 HLA allele in a sample obtained from said subject, wherein expression of the B35 HLA allele indicates that said subject will respond therapeutically to the method of treating cancer, and
administering to said subject an immunogenic composition comprising one or more tumor cell lines allogeneic to said subject.

18. The method of claim 17 , wherein the immunogenic composition comprises one or more tumor cell lines selected from the group consisting of human cell lines designated SH-M-20, SH-M-20-A2, SH-M-21, SH-O-30 and SH-L-40 that are deposited in the ECACC under the accession numbers 11052602, 11052604, 11052601, 11052603 and 11052605, respectively.

19. A method for treating, ameliorating, or reducing cancer in a mammalian subject, the method comprising administering to said subject a therapeutically effective amount of a therapeutic composition comprising at least two allogeneic cell lines, wherein:
at least one of said cell lines expresses at least one HLA allele identical to the HLA alleles of said subject,
at least one of said cell lines endogenously or exogenously expresses the HLA-B35 allele,
and wherein said at least one of said cell lines express at least one HLA antigens and/or tumor associated antigens selected from the group consisting of A24, A33, B49, CW04, CW12, A2, A24, A03, A25, B08, B18, DRB1, A26, A28, B35, DRB01, DRB104, GD3, S-100, HMB45, Melan A/MART-I, HMW, MSCA, CD146, MAGE-A1, MAGE-A3, NY-ESO-1, CEA, PAN cytokeratin, Ca-125-sec, CEA-sec, CA15-3-sec and MUC-1,
said composition further comprising a pharmaceutically acceptable carrier, diluent, excipient, hapten, adjuvant or additive.

20. The method of claim 19 , wherein said cancer is selected from the group consisting of melanoma, carcinoma, leukemia, sarcoma, myeloma and lymphoma.

21. The method of claim 20 , wherein said subject expresses the B35 HLA allele.

22. The method of claim 19 ,

Assignees

• Hadasit Med Res Service
• Hadasit Med Res Service

Inventors

• Peretz Tamar
• Lotem Michal
• Machlenkin Arthur
• Frankenburg Shoshana
• Ben David Inna
• Kuznetz Anna
• Gelfand Yael
• Eisenberg Galit
• Darash Yahana Merav

Classifications

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12N5/0693

  Tumour cells; Cancer cells · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• A61K39/0011 Primary

  Cancer antigens · CPC title

• G01N33/57492

  Physics · mapped topic